JAZZ Q1 2021 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$608M+13.6% YoY

Gross Profit

$567M93.4% margin

Operating Income

$162M26.7% margin

Net Income

$122M20.1% margin

EPS (Diluted)

$2.09

QoQ Revenue Growth

-8.7%

Cash Flow

Operating Cash Flow

$285M

Free Cash Flow

$283M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$6.8B

Total Liabilities

$3.0B

Stockholders' Equity

$3.8B

Cash & Equivalents

$2.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$608M	$535M	+13.6%
Gross Profit	$567M	$506M	+12.1%
Operating Income	$162M	-$190M	+185.5%
Net Income	$122M	-$158M	+177.2%

Revenue Segments

Xyrem

$336M56%

Xywav

$75M12%

Zepzelca

$54M9%

Defitelio/Defibrotide

$50M8%

Erwinaze And Erwinase

$41M7%

Vyxeos

$33M5%

Sunosi

$12M2%

Other Products

$3M0%

Geographic Segments

UNITED STATES

$548M90%

Europe

$47M8%

Other Countries

$12M2%